CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Phase 3

Completed

Conditions: Malignant Melanoma

Interventions: Drug: ABI-007
Drug: Dacarbazine

First Posted Date: 2009-03-18

Last Posted Date: 2019-10-30

Lead Sponsor: Celgene

Target Recruit Count: 529

Registration Number: NCT00864253

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
Mary Crowley Research Center, Dallas, Texas, United States
🇦🇺
Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia

and more 108 locations

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Phase 3

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Albumin-bound paclitaxel (ABI-007)
Drug: Gemcitabine

First Posted Date: 2009-02-16

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 861

Registration Number: NCT00844649

Locations: 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
Phoebe Putney Cancer Center, Albany, Georgia, United States
🇺🇸
Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States

and more 188 locations

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone
Drug: Aspirin

First Posted Date: 2009-02-02

Last Posted Date: 2016-04-27

Lead Sponsor: Celgene Corporation

Target Recruit Count: 259

Registration Number: NCT00833833

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 16 locations

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Phase 1

Withdrawn

Conditions: Solid Tumor

Interventions: Drug: ABI-010

First Posted Date: 2009-01-12

Last Posted Date: 2018-04-11

Lead Sponsor: Celgene

Registration Number: NCT00820768

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Lenalidomide

First Posted Date: 2008-12-22

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 11

Registration Number: NCT00812968

Locations: 🇯🇵
Celgene Clinical Site, Shizuoka, Japan

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Phase 3

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: Lenalidomide

First Posted Date: 2008-10-17

Last Posted Date: 2021-12-02

Lead Sponsor: Celgene

Target Recruit Count: 317

Registration Number: NCT00774345

Locations: 🇺🇸
Pacific Coast Hematology Oncology, Fountain Valley, California, United States
🇺🇸
Memorial Hospital, Hollywood, Florida, United States
🇺🇸
The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 237 locations

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Romidepsin

First Posted Date: 2008-10-02

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT00765102

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
🇺🇸
Desert Cancer Care, Inc, Rancho Mirage, California, United States

and more 9 locations

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Phase 1

Completed

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes
Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia

Interventions: Drug: azacitidine

First Posted Date: 2008-09-29

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT00761722

Locations: 🇺🇸
California Cancer Care Inc, Greenbrae, California, United States
🇺🇸
Main Cancer Centers of Florida, P.A., Ocoee, Florida, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 8 locations

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: ACE-011
Biological: Placebo

First Posted Date: 2008-09-04

Last Posted Date: 2024-10-03

Lead Sponsor: Celgene

Target Recruit Count: 30

Registration Number: NCT00747123

Locations: 🇷🇺
Investigative Site, Saint-Petersburg, Russian Federation

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: lenalidomide

First Posted Date: 2008-08-19

Last Posted Date: 2018-12-13

Lead Sponsor: Celgene

Target Recruit Count: 134

Registration Number: NCT00737529

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Tower Cancer Research Foundation, Los Angeles, California, United States

and more 67 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy